- Three UK hospitals begin trial of Paige’s AI technology for prostate cancer diagnosis.
- The AI, known as the Prostate Suite, assists pathologists in detecting and grading tumors.
- The study, led by the University of Oxford, aims to improve patient outcomes and efficiency.
The ARTICULATE PRO study, spearheaded by the University of Oxford in collaboration with Paige, has commenced across three hospital systems in England. North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust are incorporating Paige’s AI technology, the Prostate Suite, into their standard care.
This AI system is designed to aid pathologists in detecting, grading, and measuring tumors in prostate biopsies and tissue samples, potentially enhancing the accuracy and efficiency of prostate cancer diagnosis.
AI Revolutionizes Prostate Cancer Detection in UK Hospitals
This trial is notable for its diverse implementation across hospitals using different digital pathology scanners and serving varied patient populations. Such diversity allows for a comprehensive assessment of the AI’s impact on clinical decision-making, pathology service delivery, and resource utilization. Funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, this study could lead to broader adoption of AI in cancer diagnosis, potentially transforming patient care in the UK and beyond.
Led by the University of Oxford, the trial leverages the advanced capabilities of the Prostate Suite, which assists pathologists in the detection, grading, and measurement of tumors in prostate biopsies and tissue samples. This AI technology promises to enhance the accuracy and consistency of pathology assessments, addressing the increasing rates of prostate cancer.
Professor Clare Verrill, the principal investigator of ARTICULATE PRO, highlighted the patient-centered approach of the study, emphasizing the goal of ensuring patients benefit from powerful AI technology. Dr. Jon Oxley, a uropathologist and Bristol lead of the study, underscored the significant advancement that Paige’s AI represents, noting its validated performance for safe and effective clinical use.
The trial’s implementation across hospitals with varied digital pathology systems and patient populations allows for a thorough evaluation of the AI’s impact in real-world settings. Funded by the AAC Artificial Intelligence in Health and Care Award, the study aims to set a precedent for the integration of AI in cancer diagnosis, potentially paving the way for widespread adoption in healthcare systems globally.
The ARTICULATE PRO study holds the promise of revolutionizing prostate cancer diagnosis through the integration of advanced AI technology, potentially leading to earlier detection, more accurate grading, and improved patient outcomes.
“We believe AI can help to improve the accuracy and consistency of grading cancer and assist in detection of small areas of cancer which are easy to miss.” – Dr. Bidisa Sinha
